Ibritumomab tiuxetan plus rituximab as initial therapy for patients with high tumor burden, indolent histology non-Hodgkin's lymphoma.
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2018
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Rituximab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 12 Jun 2018 Status changed from completed to discontinued.
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Dec 2011 Planned Eed date changed from 1 Dec 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.